TLR9 and colon adenocarcinoma: Here, we have described the superior antitumor efficacy of co-delivering docetaxel chemotherapy and TLR9 agonist CpG on sHDL nanoparticles to MC-38 colon adenocarcinoma tumors when compared to docetaxel alone.